Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Puhan MA, Singh S, Weiss CO, Varadhan R, Boyd CM.

BMC Med Res Methodol. 2012 Nov 19;12:173. doi: 10.1186/1471-2288-12-173. Review.

2.

Methods for Benefit and Harm Assessment in Systematic Reviews [Internet].

Boyd CM, Singh S, Varadhan R, Weiss CO, Sharma R, Bass EB, Puhan MA.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

3.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
4.

[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].

Amato L, Colais P, Davoli M, Ferroni E, Fusco D, Minozzi S, Moirano F, Sciattella P, Vecchi S, Ventura M, Perucci CA.

Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Review. Italian.

5.

Methods for the comparative evaluation of pharmaceuticals.

Zentner A, Velasco-Garrido M, Busse R.

GMS Health Technol Assess. 2005 Nov 15;1:Doc09.

6.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
7.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
8.

Evaluating non-randomised intervention studies.

Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group.

Health Technol Assess. 2003;7(27):iii-x, 1-173. Review.

9.

Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.

Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D, Bond GR, Huxley P, Tyrer P.

Health Technol Assess. 2001;5(21):1-75. Review.

10.

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.

Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW.

Value Health. 2010 Aug;13(5):657-66. doi: 10.1111/j.1524-4733.2010.00725.x. Epub 2010 Apr 15. Review.

11.

Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations.

Fain KM, Yu T, Li T, Boyd CM, Singh S, Puhan MA.

J Clin Epidemiol. 2016 Jun;74:151-7. doi: 10.1016/j.jclinepi.2016.02.018. Epub 2016 Mar 3.

PMID:
26939932
12.

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J.

Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. Review.

13.

A first step to assess harm and benefit in clinical trials in one scale.

Boers M, Brooks P, Fries JF, Simon LS, Strand V, Tugwell P.

J Clin Epidemiol. 2010 Jun;63(6):627-32. doi: 10.1016/j.jclinepi.2009.07.002. Epub 2009 Oct 1. Review.

PMID:
19800197
14.

Second-generation antidepressants for preventing seasonal affective disorder in adults.

Gartlehner G, Nussbaumer B, Gaynes BN, Forneris CA, Morgan LC, Kaminski-Hartenthaler A, Greenblatt A, Wipplinger J, Lux LJ, Sonis JH, Hofmann J, Van Noord MG, Winkler D.

Cochrane Database Syst Rev. 2015 Nov 8;(11):CD011268. doi: 10.1002/14651858.CD011268.pub2. Review.

PMID:
26558418
15.

[A research roadmap for complementary and alternative medicine - what we need to know by 2020].

Fischer F, Lewith G, Witt CM, Linde K, von Ammon K, Cardini F, Falkenberg T, Fønnebø V, Johannessen H, Reiter B, Uehleke B, Weidenhammer W, Brinkhaus B.

Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24.

16.
17.

Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis.

Yu T, Holbrook JT, Thorne JE, Puhan MA.

Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):363-71. doi: 10.1002/pds.3959. Epub 2016 Jan 22.

18.

Interventions to reduce harm from continued tobacco use.

Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, Begh R, Farley A, Lancaster T.

Cochrane Database Syst Rev. 2016 Oct 13;10:CD005231. Review.

PMID:
27734465
19.

Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.

Anglemyer A, Horvath HT, Bero L.

Cochrane Database Syst Rev. 2014 Apr 29;(4):MR000034. doi: 10.1002/14651858.MR000034.pub2. Review.

PMID:
24782322
20.

Supplemental Content

Support Center